Article Text

Download PDFPDF
Sensory neuronopathies: new genes, new antibodies and new concepts
  1. Guillaume Fargeot1,
  2. Andoni Echaniz-Laguna1,2,3
  1. 1 Department of Neurology, APHP, CHU de Bicêtre, Le Kremlin-Bicêtre, France
  2. 2 French National Reference Center for Rare Neuropathies (NNERF), Le Kremlin-Bicêtre, France
  3. 3 INSERM U1195, Paris-Saclay University, Le Kremlin-Bicêtre, France
  1. Correspondence to Dr Guillaume Fargeot, Department of Neurology, APHP, CHU de Bicêtre, Le Kremlin-Bicetre, France; guillaume.fargeot{at}


Degeneration of dorsal root ganglia (DRG) and its central and peripheral projections provokes sensory neuronopathy (SN), a rare disorder with multiple genetic and acquired causes. Clinically, patients with SN usually present with proprioceptive ataxia, patchy and asymmetric sensory abnormalities, widespread areflexia and no weakness. Classic causes of SN include cancer, Sjögren’s syndrome, vitamin deficiency, chemotherapy, mitochondrial disorders and Friedreich ataxia. More recently, new genetic and dysimmune disorders associated with SN have been described, including RFC1 gene-linked cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) and anti-FGFR3 antibodies. In this review, we detail the pathophysiology of DRG degeneration, and the genetic and acquired causes of SN, with a special focus on the recently described CANVAS and anti-FGFR3 antibodies. We also propose a user-friendly and easily implemented SN diagnostic strategy.

  • neuropathy
  • peripheral neuropathology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors GF and AE-L wrote the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles